{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:04:54Z","timestamp":1784297094256,"version":"3.55.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Slow-release oral morphine (SROM) is approved for the treatment of opioid use disorder (OUD) in several European countries and has been used off label in Canada since 2017. However, the evidence base to support its use is limited and predates the fentanyl era.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the discontinuation rates and mortality risks of SROM vs methadone for the treatment of OUD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This comparative effectiveness study with a target trial emulation approach used data from observational linked health administrative databases in the Vancouver Coastal Health Authority (VCHA) region in British Columbia, Canada, between July 1, 2017, and June 30, 2024. Participants were adults aged 19 to 65 years with OUD.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n New prescription of SROM or methadone for OUD (ie, no dispensation of medications for OUD in the 7 days prior) within VCHA clinical services.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Estimated 12-month risk of treatment discontinuation (\u22657 days without medication dispensation) and all-cause mortality, as well as treatment adherence (proportion of days covered [PDC]) over 12 months of follow-up. Both intention-to-treat (ITT) and per-protocol (PP; restricted to episodes where SROM or methadone was dispensed within 4 days of the prescription) analyses were conducted.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 3254 unique individuals (median age, 37 [IQR, 30-46] years; 2088 [64.2%] male) contributed to 4059 person-trials (2737 [67.4%] methadone, 1322 [32.6%] SROM) for the ITT analysis, and 1992 unique individuals contributed to 2276 person-trials (1653 [72.6%] methadone, 623 [27.4%] SROM) for the PP analysis. In ITT analyses, the standardized cumulative incidence of discontinuation at 12 months was 99.3% (95% CI, 99.0%-99.5%) and 97.9% (95% CI, 97.5%-98.2%) in the SROM and methadone arms, respectively (adjusted risk difference [ARD], 1.4 percentage points [pp]; 95% CI, 1.0-1.9 pp). PDC was also lower in the SROM group (adjusted risk ratio, 0.89; 95% CI, 0.87-0.91), while mortality risk was similar between arms (ARD, 1.1 pp; 95% CI, \u22121.3 to 4.1 pp). Of 121 total deaths, only 2 (1.7%) occurred when people were receiving MOUD. PP analyses yielded similar results.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this comparative effectiveness study of adults with OUD in a Canadian setting, treatment discontinuation was common. Compared with methadone, SROM was associated with a slightly higher risk of treatment discontinuation and lower adherence but similar mortality risk. The findings suggest either medication may be appropriate if measures are in place to support retention.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.2970","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:00:16Z","timestamp":1774364416000},"page":"e262970","source":"Crossref","is-referenced-by-count":1,"title":["Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder in the Fentanyl Era"],"prefix":"10.1001","volume":"9","author":[{"given":"M. Eugenia","family":"Socias","sequence":"first","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Lei","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Zhou","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Anand","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishan","family":"Cui","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Penta","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Larochelle","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lodi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"1","key":"zoi260123r3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"zoi260123r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"zoi260123r5","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"zoi260123r6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"6","key":"zoi260123r7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders.","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"zoi260123r8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jama.2024.11977","article-title":"Major gaps in the cascade of care for opioid use disorder: implications for clinical practice.","volume":"332","author":"Arwady","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"zoi260123r9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/add.14947","article-title":"The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.","volume":"115","author":"Piske","year":"2020","journal-title":"Addiction"},{"key":"zoi260123r10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1472-6963-11-174","article-title":"Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.","volume":"11","author":"Marchand","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"zoi260123r11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/00952991003736371","article-title":"The role of patient satisfaction in methadone treatment.","volume":"36","author":"Kelly","year":"2010","journal-title":"Am J Drug Alcohol Abuse"},{"key":"zoi260123r12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/PPA.S52060","article-title":"A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study.","volume":"8","author":"Trujols","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"zoi260123r13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799","article-title":"Slow release oral morphine versus methadone for the treatment of opioid use disorder.","volume":"9","author":"Klimas","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"zoi260123r16","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline.","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"2","key":"zoi260123r17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.7326\/M17-2373","article-title":"Evaluating slow-release oral morphine to narrow the treatment gap for opioid use disorders.","volume":"168","author":"Soc\u00edas","year":"2018","journal-title":"Ann Intern Med"},{"key":"zoi260123r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105993","article-title":"Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): protocol for a non-inferiority randomized clinical trial.","volume":"91","author":"Socias","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"zoi260123r19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/29767342241279167","article-title":"Redesigning a stopped clinical trial as an emulated trial using real-world data to explore the effectiveness of slow-release oral morphine as a treatment for opioid use disorder.","volume":"46","author":"Anand","year":"2025","journal-title":"Subst Use Addctn J"},{"issue":"8","key":"zoi260123r20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"9","key":"zoi260123r21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"zoi260123r22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1465-3362.2009.00145.x","article-title":"Modelling crack cocaine use trends over 10 years in a Canadian setting.","volume":"29","author":"Werb","year":"2010","journal-title":"Drug Alcohol Rev"},{"key":"zoi260123r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102696","article-title":"Trajectories of retention in opioid agonist therapy in a Canadian setting.","volume":"77","author":"Soc\u00edas","year":"2020","journal-title":"Int J Drug Policy"},{"key":"zoi260123r26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.drugpo.2016.09.003","article-title":"Rethinking retention in treatment of opioid dependence\u2014the eye of the beholder.","volume":"39","author":"Vogel","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"7","key":"zoi260123r28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/aje\/kwq472","article-title":"Implementation of G-computation on a simulated data set: demonstration of a causal inference technique.","volume":"173","author":"Snowden","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"9","key":"zoi260123r29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2022.1271","article-title":"Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation.","volume":"327","author":"Gomes","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"zoi260123r30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s11469-022-00985-w","article-title":"Impact of alternative ways to operationalize buprenorphine treatment duration on understanding continuity of care for opioid use disorder.","volume":"22","author":"Dong","year":"2024","journal-title":"Int J Ment Health Addict"},{"issue":"2","key":"zoi260123r34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/EDE.0000000000001697","article-title":"Comparative analysis of instrumental variables on the assignment of buprenorphine\/naloxone or methadone for the treatment of opioid use disorder.","volume":"35","author":"Homayra","year":"2024","journal-title":"Epidemiology"},{"issue":"21","key":"zoi260123r35","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder.","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"zoi260123r36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance.","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"zoi260123r37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"issue":"6","key":"zoi260123r38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009879.pub2","article-title":"Slow-release oral morphine as maintenance therapy for opioid dependence.","volume":"2013","author":"Ferri","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"zoi260123r39","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1365-2125.2011.03923.x","article-title":"Slow-release oral morphine for opioid maintenance treatment: a systematic review.","volume":"71","author":"Jegu","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"zoi260123r40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ypmed.2016.08.008","article-title":"A review of the literature on contingency management in the treatment of substance use disorders, 2009-2014.","volume":"92","author":"Davis","year":"2016","journal-title":"Prev Med"},{"issue":"5","key":"zoi260123r43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamapsychiatry.2023.0310","article-title":"Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among Medicare beneficiaries before and during the COVID-19 pandemic.","volume":"80","author":"Jones","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi260123r44","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1097\/ADM.0000000000000606","article-title":"Mortality among people with opioid use disorder: a systematic review and meta-analysis.","volume":"14","author":"Bahji","year":"2020","journal-title":"J Addict Med"},{"issue":"3","key":"zoi260123r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0477","article-title":"Office-based addiction treatment retention and mortality among people experiencing homelessness.","volume":"4","author":"Fine","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260123r46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s11606-022-07732-w","article-title":"Variation in clinical characteristics and longitudinal outcomes in individuals with opioid use disorder diagnosis codes.","volume":"38","author":"Powell","year":"2023","journal-title":"J Gen Intern Med"},{"key":"zoi260123r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104119","article-title":"Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada: a population-based time series analysis.","volume":"118","author":"Ledlie","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi260123r48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/ADM.0b013e3181cc9610","article-title":"Patients\u2019 reasons for choosing office-based buprenorphine: preference for patient-centered care.","volume":"4","author":"Korthuis","year":"2010","journal-title":"J Addict Med"},{"issue":"3","key":"zoi260123r49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/add.13622","article-title":"Patient-centered methadone treatment: a randomized clinical trial.","volume":"112","author":"Schwartz","year":"2017","journal-title":"Addiction"},{"key":"zoi260123r50","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2147\/PPA.S109641","article-title":"Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials.","volume":"10","author":"Barrio","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"zoi260123r1","unstructured":"Government of Canada. Opioid- and stimulant-related harms in Canada. December 11, 2025. Accessed January 1, 2026. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/#a4"},{"key":"zoi260123r2","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? LM, Sutton? P. Provisional drug overdose death counts. National Vital Statistics System, National Center for Health Statistics. Accessed January 1, 2026. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi260123r14","unstructured":"European Union Drugs Agency. Statistical bulletin 2024 home\u2014latest data and statistics on the drug situation in Europe. June 11, 2024. Accessed March 24, 2025. https:\/\/www.euda.europa.eu\/data\/stats2024_en"},{"key":"zoi260123r15","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. Department of Health. 2017. Accessed January 13, 2026. https:\/\/assets.publishing.service.gov.uk\/media\/5a821e3340f0b62305b92945\/clinical_guidelines_2017.pdf"},{"key":"zoi260123r24","unstructured":"Quality Payment Program. Quality ID #468 (NQF 3175): continuity of pharmacotherapy for opioid use disorder (OUD). Centers for Medicare & Medicaid Services. 2017. Accessed March 24, 2025. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_468_MIPSCQM.pdf"},{"key":"zoi260123r25","unstructured":"British Columbia Centre on Substance Use. A guideline for the clinical management of opioid use disorder: 2023 update. British Columbia Ministry of Health and British Columbia Ministry of Mental Health and Addictions. November 2023. Accessed January 13, 2026. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/11\/BC-OUD-Treatment-Guideline_2023-Update.pdf"},{"key":"zoi260123r27","unstructured":"British Columbia Centre on Substance Use. Opioid use disorder: practice update. January 2022. Accessed May 3, 2025. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/02\/Opioid-Use-Disorder-Practice-Update-February-2022.pdf"},{"key":"zoi260123r31","unstructured":"British Columbia Centre on Substance Use. Opioid agonist treatment alert\u2014March 26, 2021: potential temporary shortage of slow-release oral morphine. February 8, 2018. Accessed January 13, 2026. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2021\/03\/OAT-Treatment-Alert-Kadian-Shortage-26Mar2021.pdf"},{"key":"zoi260123r32","unstructured":"British Columbia Ministry of Health. Drug shortages. Updated February 4, 2026. Accessed May 3, 2025. https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/pharmacies\/drug-shortage-information"},{"key":"zoi260123r33","unstructured":"Drug shortages Canada. Accessed May 3, 2025. https:\/\/healthproductshortages.ca\/"},{"key":"zoi260123r41","unstructured":"Bromley? L, Kahan? M, Regenstreif? L, Srivastava? A, Wyman? J. Methadone treatment for people who use fentanyl: recommendations. Mentoring, Education, and Clinical Tools for Addiction\u2013Partners in Health Integration. June 30, 2021. Accessed January 13, 2026. https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_MethadoneForFentanyl.pdf"},{"key":"zoi260123r42","unstructured":"American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. 2020. Accessed January 13, 2026. https:\/\/www.asam.org\/quality-care\/clinical-guidelines\/national-practice-guideline"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846926\/socias_2026_oi_260123_1773780396.51779.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:00:23Z","timestamp":1774364423000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.2970","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}